Back to Clinical Trials Page
BRAIN
2007-0604	NWBT 020221A: A Phase II Clinical Trial Evaluating DCVax-Brain, Autologous Dendritic Cells Pused with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforms (GBM) - OPEN UIC
	A Prospective, Multi-Center Trial of NovoTTF-100A Compared to Best Stnadard of Care in Patients with Progressive or Recurrent GBM - OPEN UIC
	Monitoring Brain Tumor Response to Radiation Treatment Using Sodium MR Imaging - OPEN UIC
BREAST
2009-0254	CALGB 40502: A RAndomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxedl or Ixabepilone Combined with Bevacizumab as First-line Therapy for Locally Recurrent or Metastatic Breast Cancer - OPEN UIC
2008-0890	S0307: Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer - OPEN UIC
2008-0725	E5103: A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer - OPEN UIC
2008-0540	E1105: A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-Expressing Metastatic Breast Cancer - OPEN UIC
2008-0211	SWOG S0226: Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer - OPEN UIC
2008-0157	CALGB 40302: Endocrine Therapy with or without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant with or without Lapatinib (GW572016) for Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer - OPEN UIC
2007-0016	ECOG PACCT-1: Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial - OPEN UIC
2003-0692	CALGB 40101: Cyclophosphamide and Doxorubicin (CA) (4 VS 6 Cycles) as Adjuvant Therapy for Women with Node-Negative Breast Cancer: A 2x2 Factorial Phase III Randomized Study - OPEN
CANCER CONTROL
2007-0888	URCC07004: Assessment of Topical Treatment Response with Amitriptyline and Ketamine: Combination Trial in Chemotherapy Peripheral Neuropathy (ATTRACT-CPN) - UIC OPEN - JBVAMC OPEN
2006-0213	S0424: Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men - UIC OPEN - JBVAMC OPEN
2005-0859	URCCOP U1701: Dyspnea in Cancer Patients - OPEN UIC - PENDING JBVAMC
CHEMO PREVENTION
2001-0200	CALGB 79803: Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer - OPEN UIC- OPEN JBVAMC
GI
2008-1099	Bayer 12414: A Phase III Randomized, Douvle-Blind, Placebo-Controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma After Surgical Resection or Local Ablation - OPEN UIC - OPEN JBVAMC
2008-0676	E5202: A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers - ON HOLD UIC
2008-0677	S0000D: A Study of the Effects of Vitamin E and/or Selenium on Adenomatous Colorectal Polyps (ACP) in Participants Enrolled in SELECT Phase III Ancillary to S0000 -SELECT - OPEN UIC
2007-0581	Comparison of Hepatocellular Carcinoma Treatments at the University of Illinois at Chicago Medical Center with the SEER and SEER-Medicare Databases - OPEN UIC - OPEN JBVAMC
GU/REN/PROSTATE
2008-0736	S0421: Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer - OPEN UIC
2008-0149	E2804: The BeST Trial: A Randomized Phase II Study of VEGF, RAF kinase, and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma - OPEN UIC
2004-0677	CALGB 90202: A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to the Bone - OPEN UIC- OPEN JBVAMC
GYNE/ONC
2008-0702	GOG 207: A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, in the Treatment of Patients with Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or 3) - OPEN UIC
2008-0535	Precision Therapeutics: ChemoFx Observational Study: A Non-Interventional, Longitudinal, Multi-Center Initiative Examining Outcomes Associated with the Use of the ChemoFx Assay in Solid Tumor Malignancies - OPEN UIC
2008-0534	GOG 232C: A Phase II Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin NSC #241240), and BSI-201 (NSC 3746045, IND#71,677) in the treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma - OPEN UIC
2008-0533	GOG 238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus - OPEN UIC
2003-0187	GOG 187: Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-line Therapy - OPEN UIC
2008-0020	GOG 213: A Phase III Randomized Contolled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cryoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer - OPEN UIC
2007-0811	GOG 215: A Phase II Randomized Study of the Effect of Zoledronic Acid Versus Observation on Bone Mineral Density of the Lumbar Spine in Women Who Elect to Undergo Surgery that Results in Removal of Both Ovaries - OPEN UIC
2007-0797	GOG 235: Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epthelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy - OPEN UIC
2007-0599	GOG 224: Randomized, Contolled Phase II Evaluation of Megestrol in Different Dose and Sequence in the Treatment of Endometrial Intrapithelial Neoplasia (EIN) from a Referred Cohort of Atypical Endometrial Hyperplasia (AEH) or EIN - OPEN UIC
2006-0081	GOG 219: A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIB, IIIB and IVA Cervical Carcinoma Limited to the Pelvis - OPEN UIC
2005-0802	GOG 218: A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC #704865, IND #7921) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women with Newly Diagnosed, Previously Untreated, Suboptimal Advanced Stage Epithelial Ovarian and Primary Peritoneal Cancer - OPEN UIC
2005-0641	GOG 212: A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel of XYOTAX (CT-2103) (IND#70177), No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy - OPEN UIC
2004-0488	GOG 205: A Phase II Trial of Radiation Therapy and Weekly Cisplatin Chemotherapy for the treatment of Locally-Advanced Squamous Cell Carcinom of the Vulva - OPEN UIC
2004-0208	GOG 0136: Acquisition of Human Gynecologic Specimens and Serum to be used in Studying the Causes, Diagnosis, Prevention, and Treatment of Cancer - OPEN UIC
2004-0021	GOG 0210: A Molecular Staging Study of Endometrial Carcinom -OPEN UIC
2003-0765	GOG 0209: Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer - OPEN UIC
HEAD AND NECK
2008-0837	E1305: A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab In Patients with Recurrent Or Metastatic Head and Neck Cancer - OPEN UIC
2005-0510	Phase I Study of Concomitant Cisplatin and Intensity-Modulated Radiation Therapy (IMRT) with a Simultaneous Integrated Boost (SIB) for Resected Advanced Head and Neck - OPEN UIC
HEME
2008-0578	MPD-RC 104: A Multicenter, Open Label Phase I/II Study of CEP-701 (Lestaurtinib) in Adults with Myelofibrosis - OPEN UIC
2008-0319	MPD-RC 103: Phase II Study of Bevacizumab (Avastin) in Myelofibrosis - OPEN UIC
2007-0538	MPD-RC 105: Molecular Biology of Familial Myeloproliferative Disorders - OPEN UIC
2007-0065	MPD-RC 101: Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis - OPEN UIC
2006-0147	UC13437B: A Phase I/II Study of Busulfan-Fludarabine Conditioning and T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients with Advanced Hematologic Malignancies - OPEN UIC
2000-0117	Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies - OPEN UIC
LEUKEMIA
2009-0110	CALGB 10503: Phase II Study of Maintenance Therapy with Decitabine (NSC #127716, IND #50733) Following Standard Induction and Cytogenetic Risk-Adapted intensification in Previously Untreated Patients with AML <60 Years - OPEN UIC
2008-0753	E1905: A Randomized Phase II Trial of Azacitidine with or without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage Dusplasia - ON HOLD UIC
2008-0448	CALGB 10603: A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND# 101261) or Placebo in Newly Diagnosed Patients <60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML) - OPEN UIC
2007-0889	Selenium as an Adjuvant to Imatinib Therapy - UIC OPEN - JBVAMC OPEN
LYMPHOMA
2008-0992	CALGB 50303: Phase III Randomized Study of R-CHOP versus Dose Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas - OPEN UIC
2008-0405	CALGB 50701: A Phase II Trial of Extended Induction Epratuzumab (Anti-CD22 Monoclonal Antibody) (CALGB IND #101241) plus Rituximab in Previously Untreated Follicular Non-Hodgkin’s Lymphoma (NHL) - OPEN UIC
2002-0738	CALGB 10002: Phase II Study of Rituximab and Short Duration, High Intensity Chemotherapy with G-CSF Support in Previously Untreated Patients with Burkitt Lymphoma/Leukemia - OPEN UIC
MELANOMA
2001-0187	S0008: Phase III Trial of High Dose Interferon Alpha-2b Versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients with High Risk Melanoma - OPEN UIC
MYELOMA
2009-0035	S0777: A Randomized Phase II Trial of CC-5013 (Lenalidomide, NSC-703813) and Low Dose Dexamethasone (LLD) versus Bortezomib (PS-341, NSC-681239), Lenolidomide and Low Dose Dexamethasone (BLLD) for Induction in Patients - OPEN UIC
2008-0528	E1A06: An Intergroup Phase III Randomized Controlled Trial Compapring Melphalan, Prednisone and Thalidomide Versus Melphlan, Prednisone and Lenalidomide in Newly Diagnosed Myelom Patients Who Aren Not Candidates for High-Dose Therapy - OPEN UIC
2005-0118	CALGB 100104: A Phase III Randomized, Double-Blind Study of Maintenance Therapy with CC-5013 (NSC#703813, IND#70116) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma - OPEN UIC
ORAL MEDICINE
2006-0084	Risk and Outcomes of Mucositis in Subjects Being Treated for Breast, Colorectal, Head and Neck, Non-Small Cell Lung, or Ovarian Cancers - UIC OPEN - JBVAMC PENDING
2002-0562	A Phase II, Multicenter, Double-Blind, Placebo Control Parallel Group, Dose Ranging Study of the Effects of RK-0202 on Oral Mucositis in Patients Receiving Radiation Therapy for Carcinoma of the Oral Cavity, Oropharynx, or Nasopharynx - OPEN UIC
PEDIATRIC ONCOLOGY
2007-0206	ARST0531: Intermediate Rhabdo
2007-0194	AAML0531: Gemtuzumab Combined with Chemotherapy for AML
2007-0177	ARST0332: Non-Rhabdomyosarcoma (NRSTS)
2007-0176	AREN0532: Low Risk Wilm's Tumor
2006-0780	AE24: Epidemiology of Infant Leukemia
2006-0552	AALL03N1: Ethnic Differences Survival After Childhood ALL
2006-0496	AREN03B2: Renal Tumors Classification, Biology, and Banking
2006-0368	ARET0331: Group B Introcular Retinoblastoma
2006-0327	AHOD0431: Low Hodgkin's Disease
2006-0153	D9902: Tissue Banking Protocol
2006-0083	ARET0332: Unilateral Retinoblastoma
2006-0067	AOST0331: Osteosarcoma
2005-0829	AALL0331: Standard Risk b-precursor ALL
2005-0623	ALTE03N1: Key Adverse Events After Childhood Cancer
2005-0615	New Learning in Long Term Survivors of Childhood Leukemia
2005-0234	ANHL0221: PTLD
2005-0186	ARST0331: Rabdomyosarcoma
2005-0147	AALL02P2: Relapsed ALL (CR> 18 months)
2004-0577	AHOD0031: Intermediate Risk Hodgkin's disease
2004-0295	AALL0232: High Risk ALL
2004-0280	AALL03B1: Classification of ALL
2004-0212	ACNS02B3: Brain Tumor Biology Study
2003-0793	ABTR01B1: Collecting and Banking Specimens
2003-0411	RB EPI Study: Environmental Risk of Retinoblastoma
2002-0429	COG ANBL0032: Chimeric Antibody in High Risk Neuro
2002-0091	COG 4941L: Wilm's Tumor
2001-0206	COG ANBL00B1: Neuroblastoma Biology Study
2000-0560	COG A5971: Lymphoblastic Lymphoma
1998-0519	COG LTFU: Long Term Follow-Up
RESPIRATORY
2008-0735	CALGB 30704: A Randomized Phase 2 Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC #736511, IND #74019) or Pemetrexed Plus Sunitinib in the Second-line Treatment of Advanced  Non-small Cell Lung Cancer  - OPEN UIC
2008-0148	Phase I Trial of Sunitinib (Sutent) Plus Topotecan in Relapsed Small Cell Lung Cancer - UIC OPEN
2007-0976	E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Completely Resected Stage 1B-IIA Non-Small Cell Lung Cancer (NSCLC) - UIC OPEN - JBVAMC OPEN
2007-0463	OSI-774-302: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Single-Agent Tarceva 9erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage 1B-IIIA Non Small Cell Lung Cancer - OPEN UIC
SARCOMA
SICKLE CELL